NCT00000842View on ClinicalTrials.gov

A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy

PHASE2CompletedINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

Not specified

Study Completion Date

February 28, 1999

Conditions
HIV InfectionsPeripheral Nervous System Disease
Interventions
DRUG

Nerve Growth Factor, Recombinant Human

Trial Locations (14)

10016

NY Univ. HIV/AIDS CRS, New York

14642

Univ. of Rochester ACTG CRS, Rochester

21287

Johns Hopkins Adult AIDS CRS, Baltimore

44106

Case CRS, Cleveland

60611

Northwestern University CRS, Chicago

90095

UCLA CARE Center CRS, Los Angeles

275997215

Unc Aids Crs, Chapel Hill

432101228

The Ohio State Univ. AIDS CRS, Columbus

943055107

Stanford CRS, Stanford

981224304

University of Washington AIDS CRS, Seattle

Unknown

San Mateo County AIDS Program, San Mateo

Washington U CRS, St Louis

Cornell University A2201, New York

02215

Beth Israel Deaconess - East Campus A0102 CRS, Boston

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000842 - A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy | Biotech Hunter | Biotech Hunter